Axitan Inc., a biotech company focused on developing endolysin-based products to replace antibiotics in the animal protein industry, has appointed Guillermo Zavala as vice president sales and marketing. Zavala will be responsible for the ongoing expansion of Axitan’s North American and international markets.
“Guillermo joins us at an exciting time. Our first two products are now gaining significant momentum in multiple markets,” said Al Zimmerman, CEO of Axitan. “Our R&D team continues to expand our Endolysin Technology Platform and gel-based delivery platform, Hatch.life. As VP of sales and marketing, we look forward to Guillermo helping expand Axitan’s business for existing and new products globally. We are excited to have him lead our commercial efforts.”
Endolysins are antimicrobial enzymes targeting pathogenic bacteria. They form the core of Axitan’s performance improving products that address productivity and bacterial challenges across species. Axitan’s antibiotic-free solutions can be delivered in multiple formats – dry feed, gel, water and solid dose.
“As a trained veterinarian, the consistent performance of Axitan’s next generation antibiotic-free products is exceptional,” Zavala said. “It is an honor to be joining the team that has pioneered this new approach to productivity and bacterial challenges in the animal protein industry through endolysins.”
Zavala was previously at Eastman Animal Nutrition where he was director of sales for the Americas. Prior to that, he spent 24 years at Evonik, where he was promoted through a range of commercial and managerial positions. Zavala holds a Doctor of Veterinary Medicine and Animal Husbandry degree from the National Autonomous University of Mexico and has a Certification in Advanced Marketing from the University of Mannheim, Germany. He is based in Georgia.
